drugset / Trial / NCT05769946
A Study of Hemay005 in Adult With Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A multicenter, randomized, double-blind, placebo-controlled, phase II study to evaluate the efficacy and safety of Hemay005 tablet in the treatment of moderate to severe atopic dermatitis.
Timeline
- Start
- 2022-11-24
- Primary completion
- 2024-01-24
- Completion
- 2024-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MUFEMILAST | Small molecule | 60 mg | — |
| Subject | MUFEMILAST | Small molecule | 75 mg | — |